|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Stanford University |
| Information provided by: | Stanford University |
| ClinicalTrials.gov Identifier: | NCT00568282 |
Purpose
The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.
| Condition | Intervention |
|
Lung Cancer |
Procedure: phlebotomy |
| MedlinePlus related topics: | Cancer Lung Cancer |
| Study Type: | Observational |
| Study Design: | Prospective |
| Official Title: | Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017) |
| Estimated Enrollment: | 100 |
| Study Start Date: | February 2007 |
The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:Inclusion Criteria (Cases):
Inclusion Criteria (Controls):
2. pregnant women
Contacts and Locations| United States, California | |||||
| Stanford University School of Medicine | Recruiting | ||||
| Stanford, California, United States, 94305 | |||||
| Contact: Lisa Zhou, MD 650-736-4112 yaya@stanford.edu | |||||
| Contact: Cancer Clinical Trials Office (650) 498-7061 | |||||
| Principal Investigator: Heather A. Wakelee | |||||
| Stanford University |
| Principal Investigator: | Heather A. Wakelee | Stanford University |
More Information
| Study ID Numbers: | SU-11052007-804, 96710, LUN0017, NCT00568282 |
| First Received: | December 4, 2007 |
| Last Updated: | May 30, 2008 |
| ClinicalTrials.gov Identifier: | NCT00568282 |
| Health Authority: | United States: Food and Drug Administration; USA:Institutional Review Board |
|
|